Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
about
Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacyFunctional foods and their role in cancer prevention and health promotion: a comprehensive review.The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.Knowledge about Human Papillomavirus and Time to Complete Vaccination among Vulnerable Female Youth.Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized studyImmunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.Awareness and knowledge of Human Papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population.Factors impacting HPV vaccination: lessons for health care professionals.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Reply to Harper.
P2860
Q28084836-4C23F7DB-6DEA-41A7-A0E5-EC9ADFE6CE2CQ33622636-7A9708EF-ACF9-4037-8ACD-9CEF3CBBFD21Q35887542-D5F67833-323B-4A0E-AF25-8AFDCE763506Q36731354-9F6D359C-1DBE-4B2A-B375-47AE02B97F81Q36977720-0B9AA3D5-3B8D-49DA-8602-154CD3BCE300Q36978399-8437A683-9052-423E-B462-25C3BD6CB380Q37118381-291B6849-FDF4-4CE8-A976-5201DEB565B7Q37135074-70F94913-6AEF-4304-96EC-F2E2BA8F620AQ37430038-61A11FC8-81E8-42FF-A343-63B1A3BB9047Q38223242-8396D47B-0628-4F6B-9013-510A4275C005Q47549756-D3D83F7F-A834-472D-83F1-C2366F9CBE75Q51850494-C3FFBE69-469E-4113-85C7-588B3EA5FAB9
P2860
Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Immunogenicity of quadrivalent ...... to 32 months after third dose.
@en
Immunogenicity of quadrivalent ...... to 32 months after third dose.
@nl
type
label
Immunogenicity of quadrivalent ...... to 32 months after third dose.
@en
Immunogenicity of quadrivalent ...... to 32 months after third dose.
@nl
prefLabel
Immunogenicity of quadrivalent ...... to 32 months after third dose.
@en
Immunogenicity of quadrivalent ...... to 32 months after third dose.
@nl
P2093
P2860
P356
P1476
Immunogenicity of quadrivalent ...... to 32 months after third dose.
@en
P2093
D Scott Lamontagne
Kathleen M Neuzil
Vu Dinh Thiem
Vu Minh Huong
Yuxiao Tang
P2860
P304
P356
10.1093/INFDIS/JIT363
P407
P577
2013-07-30T00:00:00Z